

ProBioGen and Surface Oncology sign 2nd AMP

March 9, 2018 | News

Under the terms of the agreement Surface Oncology will contract with ProBioGen to develop and manufacture another antibody for potential use in clinical trials



ProBioGen AG, German service & technology provider for complex therapeutic glycoproteins has announced the signing of second antibody development project with Cambridge, MA-based Surface Oncology Inc., an immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment.

Under the terms of the agreement Surface Oncology will contract with ProBioGen to develop and manufacture another antibody for potential use in clinical trials.

ProBioGen will develop several stable cell lines in parallel, gradually reduce the candidate number and conclude with process development and GMP manufacturing for a single antibody product candidate. The advantage of this approach is the meticulous analysis of several candidates at the same time while strongly reducing time lines.

Dr Gabriele Schneider, ProBioGen's CBO commented: "We have worked together with Surface Oncology very well for quite a while and this is now our second potential clinical antibody project together. We have established a seamless team working across our companies and we are very pleased to continue to expand this relationship with Surface Oncology."